A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non–Small Cell Lung Cancer
Open Access
- 15 March 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (6), 1794-1800
- https://doi.org/10.1158/1078-0432.ccr-06-1836
Abstract
Purpose: Bexarotene is a rexinoid (selective retinoid X receptor agonist) that affects proliferation, differentiation, and apoptosis in preclinical studies. The relationship between bexarotene levels and biomarker changes in tumor tissues has not been previously studied. Experimental Design: BEAS-2B human bronchial epithelial (HBE) cells, retinoid-resistant BEAS-2B-R1 cells, A427, H226, and H358 lung cancer cells were treated with bexarotene. Proliferation and biomarker expression were assessed. In a proof-of-principle clinical trial, bexarotene tumor tissue levels and intratumoral pharmacodynamic effects were assessed in patients with stages I to II non–small cell lung cancer. Bexarotene (300 mg/m2/day) was administered p.o. for 7 to 9 days before resection. Results: Bexarotene-induced dosage-dependent repression of growth, cyclin D1, cyclin D3, total epidermal growth factor receptor (EGFR), and phospho-EGFR expression in BEAS-2B, BEAS-2B-R1, A427, and H358, but not H226 cells. Twelve patients were enrolled, and 10 were evaluable. Bexarotene treatment was well tolerated. There was nonlinear correlation between plasma and tumor bexarotene concentrations (r2 = 0.77). Biomarker changes in tumors were observed: repression of cyclin D1, total EGFR and proliferation in one case; repression of cyclin D3, total and phospho-EGFR in another. The cases with multiple biomarker changes had high tumor bexarotene (107-159 ng/g). A single biomarker change was detected in one case with low tumor bexarotene. Conclusion: Bexarotene represses proliferation and biomarker expression in responsive, but not resistant HBE and lung cancer cells. Similar biomarker changes occur in lung tumors when therapeutic intratumoral bexarotene levels are achieved. This proof-of-principle trial approach is useful to uncover pharmacodynamic mechanisms in vivo and relate these to intratumoral pharmacokinetic effects.Keywords
Other Versions
This publication has 27 references indexed in Scilit:
- Phase II Trial of Bexarotene Capsules in Patients With Advanced Non–Small-Cell Lung Cancer After Failure of Two or More Previous TherapiesJournal of Clinical Oncology, 2006
- The Retinoic Acid Paradox in Cancer ChemopreventionJNCI Journal of the National Cancer Institute, 2006
- Bexarotene and Erlotinib for Aerodigestive Tract CancerJournal of Clinical Oncology, 2005
- A Novel Retinoic Acid Receptor β Isoform and Retinoid Resistance in Lung CarcinogenesisJNCI Journal of the National Cancer Institute, 2005
- Retinoid Targeting of Different D-Type Cyclins through Distinct Chemopreventive MechanismsCancer Research, 2005
- Nonclassical Retinoids and Lung CarcinogenesisClinical Lung Cancer, 2005
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract CancersClinical Cancer Research, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Retinoids in cancer therapy and chemoprevention: promise meets resistanceOncogene, 2003
- Synthesis and Structure-Activity Relationships of Novel Retinoid X Receptor-Selective RetinoidsJournal of Medicinal Chemistry, 1994